Lijing Wang

Dr. Lijing Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Drug Safety
Verified
Journal Article
Closed access
PDF file
YZYu Zhou
Yu Zhou
WXWenhuo Xie
Wenhuo Xie
LWLinyao Wang
Linyao Wang
XZXinyan Zhu
Xinyan Zhu
JLJianbin Li
Jianbin Li
LWLijing Wang
Lijing Wang

1 November 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
LWLinxi Wang
Linxi Wang
ZCZhou Chen
Zhou Chen
XLXiaoying Liu
Xiaoying Liu
LWLijing Wang
Lijing Wang
YZYu Zhou
Yu Zhou
LLLibin Liu
Libin Liu
High-sugar and high-fat diets cause significant harm to health, especially via metabolic diseases. In this study, the protective effects of the antidiabetic drug exenatide (synthetic exendin-4), a glucagon-like peptide 1 (GLP-1) receptor agonist, on high-fat and high-glucose (HFHG)-induced renal injuries were investigated in vivo and in vitro. In vivo and in vitro renal injury models were established. Metabolomic analysis based on 1H-nuclear magnetic resonance was performed to examine whether exenatide treatment exerts a protective effect against kidney injury in diabetic rats and to explore its potential molecular mechanism. In vivo, 8 weeks of exenatide treatment resulted in the regulation of most metabolites in the diabetes mellitus group. In vitro results showed that exendin-4 restored the mitochondrial functions of mesangial cells, which were perturbed by HFHG. The effects of exendin-4 included the improved antioxidant capacity of mesangial cells, increased the Bcl-2/Bax ratio, and reduced protein expression of cyt-c and caspase-3 activation. In addition, exendin-4 restored mesangial cell energy metabolism by increasing succinate dehydrogenase and phosphofructokinase activities and glucose consumption while inhibiting pyruvate dehydrogenase E1 activity. In conclusion, GLP-1 agonists improve renal injury in diabetic rats by ameliorating metabolic disorders. This mechanism could be partially related to mitochondrial functions and energy metabolism.

12 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LWLinxi Wang
Linxi Wang
ZZZhouyangyang Zhang
Zhouyangyang Zhang
MLMenghua Lin
Menghua Lin
LQLiqin Qi
Liqin Qi
LLLibin Liu
Libin Liu
LWLijing Wang
Lijing Wang
Objective: This study aimed to investigate the effects of PAItrap3, a novel PAI-1 inhibitor, on lipid metabolism, and autophagy pathways in diabetic mice.Methods: db/db diabetic mice were administered PAItrap3 (5.7 mg/kg/day, IV) for 21 consecutive days, and its impact on metabolic, gene expression, and lipidomic profiles was assessed. Western blot analysis was performed to examine lipid metabolism-related proteins in white adipose tissue (FASN, HSL, CPT1A, ACADM) and autophagy markers (LC3B, P62, Parkin, PGC1α, PPARGC1B). Additionally, RNA-seq and targeted lipidomics were employed to analyze gene expression and lipid metabolic alterations.Results: PAItrap3 significantly reduced blood glucose and glycated hemoglobin levels while improving insulin sensitivity. In lipid metabolism, FASN and HSL levels were upregulated, whereas CPT1A and ACADM levels were downregulated in the DMP group. Regarding the autophagy pathway, PPARGC1B, LC3B, and PGC1α expression levels were increased, while P62 and Parkin levels were decreased. Lipidomics analysis revealed that triglycerides (TG) and diacylglycerols (DG) were generally downregulated, with TG (18:2/18:2/18:2) (0.96 [0.8491, 1]), LPI (18:0) (0.96 [0.8491, 1]), and MLCL (14:3/20:4/22:6) (0.96 [0.8491, 1]) identified as key metabolites.Conclusion: This study finds that PAItrap3 modulates lipid metabolism, energy homeostasis, and autophagy pathways, thereby improving metabolic dysfunction in diabetic mice. These findings highlight its potential therapeutic value for treating diabetes-associated lipid metabolic disorders.

17 December 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
LMLi Ma
Li Ma
YXYan Xie
Yan Xie
SKSujie Ke
Sujie Ke
DLDeying Liu
Deying Liu
LWLinxi Wang
Linxi Wang
LLLibin Liu
Libin Liu
Objective: To address the overestimation of levothyroxine (L-T4) doses in conventional weight-based regimens for individuals who are overweight and obese, this study aimed to identify the most predictive body weight metrics and establish an optimized dosing model for accurate thyroid-stimulating hormone (TSH) suppression following total thyroidectomy in differentiated thyroid carcinoma (DTC). Methods: This retrospective study included 385 patients with DTC treated at our institution between October 2019 and December 2024. Patients were stratified by TSH targets (A1: <0.1 mIU/L; A2: 0.1–0.5 mIU/L; A3: 0.5–2.0 mIU/L) and body mass index (BMI) according to Chinese criteria (normal: 0.05). Postoperative TSH levels varied significantly according to BMI (P<0.05). Patients with higher BMI required higher total L-T4 doses (µg/d) (P<0.001) but lower weight-adjusted doses (µg/kg/d) (P<0.001). Adjusted body weight best predicted L-T4 dose for patients with BMI ≤ 23.9 kg/m 2 , while lean body weight was optimal for those with BMI≥24.0 kg/m 2 . The new model achieved a significantly higher rate of accurate initial dose prediction compared with that via empirical dosing (68.0% vs. 30.2%, P<0.001). Conclusion: The BMI-stratified L-T4 dosing formula based on optimized body weight metrics demonstrated improved accuracy, expediting TSH suppression and reducing adverse events.

11 July 2026 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LMLi Ma
Li Ma
SKSujie Ke
Sujie Ke
PHPeiji Huang
Peiji Huang
YCYao Chen
Yao Chen
QLQian Lin
Qian Lin
LWLijing Wang
Lijing Wang